Treats schizophrenia. ANDA 212257, held by Somerset Therapeutics. Prochlorperazine Edisylate.
As of Nov 21, 2026, ANDA 212257 (Prochlorperazine Edisylate), held by Somerset Therapeutics, was first approved by FDA on Sep 13, 2024, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE To control severe nausea and vomiting. For the treatment of schizophrenia. Prochlorperazine has not been shown effective in the management of behavioral complications in patients with mental retardation.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 13, 2024 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Prochlorperazine EdisylateEQ 5MG BASE/ML · injectable;injection | Prochlorperazine Edisylate | Rx |
| Apr 1, 2026 | Supplement 1Labeling · Standard review | Approved | None posted |
| Sep 13, 2024 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters